Removing zelnecirnon means the biotech’s sole remaining clinical-stage asset is tivumecirnon, a phase 2 oncology med being ...

Patient Enrolled at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital Aethlon's Trial is a Safety, Feasibility, and Dose Finding Study of the Hemopurifier® ...

Vaccinex has global commercial and development rights to pepinemab and is the sponsor of the KEYNOTE-B84 study which is being performed in collaboration with Merck Sharp & Dohme Corp, a subsidiary of ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

"Paris seemed to represent a renaissance as far as Olympics go with strong viewership, effective utilization of Peacock in a ...

When Wiley Harp discovered blood in his urine on September 20, 2023, he knew something was wrong. An X-ray at Baptist-St.

V940 is an investigational individualized neoantigen therapy under development in combination with Keytruda (pembrolizumab) as adjuvant treatment for resectable Stage II, IIIA or IIIB (N2 ...

Search Engine Land » PPC » Amazon non-endemic ads: Winning strategies for service-based businesses Chat with SearchBot Please note that your conversations will be recorded. SearchBot ...

in combination with Keytruda, Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with resectable Stage II, IIIA or IIIB non-small cell lung cancer who did not achieve a pathological ...

The INTerpath-009 trial will investigate an individualized neoantigen therapy plus Keytruda in patients with non-small cell lung cancer post-surgery whose disease didn't fully respond to prior ...

By Garett Sloane - 3 hours 44 min ago By Ewan Larkin - 4 hours 14 min ago By E.J. Schultz - 4 hours 14 min ago By Tim Nudd - 4 hours 14 min ago By Brian Bonilla - 21 hours 13 min ago By Ad Age ...